Abstract
iVexSol, a contract development and manufacturing organization (CDMO) that produces lentiviral vectors (LVVs), has raised $23.8 million in series A-3 financing. New investors Bristol Myers Squibb, Asahi Kasei Medical, and Charles River Laboratories joined existing investors to bring the total in series A fundng to over $39 million, according to the company. iVexSol says it will use the money to invest in its intelligent vector solutions by advancing technologies, growing technical teams, and building on current infrastructure “to support the production of stable LVV producer cell lines.”
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
